UroGen Pharma CMO Mark Schoenberg sells $37,383 in shares By Investing.com

Mark Schoenberg, Chief Medical Officer at UroGen Pharma Ltd. (), reported recent transactions involving the company’s ordinary shares, according to a filing with the U.S. Securities and Exchange Commission.

On September 8, 2026, Mr. Schoenberg disposed of 871 ordinary shares at a price of $42.92 per share, for a total value of $37,383. These shares were sold to satisfy withholding tax obligations upon the settlement of restricted stock units (RSUs). The stock currently trades at $44.78, up significantly from its 52-week low of $15.86, reflecting a remarkable one-year return of nearly 112%.

The day prior, on September 7, 2026, Mr. Schoenberg acquired 1,667 ordinary shares through the settlement of restricted stock units. Each RSU represents a contingent right to receive one ordinary share of UroGen Pharma.

Following these reported transactions, Mr. Schoenberg directly holds 59,882 ordinary shares. According to InvestingPro analysis, URGN appears slightly undervalued at current levels, with the stock showing strong momentum despite notable volatility. The platform offers 12 additional ProTips for URGN, plus a comprehensive Pro Research Report covering the company’s financial health and growth prospects. The RSUs involved were part of an original grant on September 7, 2023, representing 5,000 ordinary shares, which are scheduled to vest in three equal annual installments starting from September 7, 2024.

In other recent news, UroGen Pharma reported impressive second-quarter 2026 financial results. The company achieved a revenue of $72.5 million, surpassing the forecast of $62.82 million. This increase was largely driven by the successful commercial launch of its bladder-cancer drug, ZUSDURI. Notably, the company’s net loss narrowed to $14.4 million, or $0.28 per share, aligning closely with the expected loss of $0.2829 per share. Guggenheim responded to these results by raising its price target for UroGen Pharma to $58 from $42, maintaining a Buy rating due to the company’s sales performance. Additionally, product sales exceeded expectations, with ZUSDURI product revenue reaching $50.4 million, a 73% increase from the previous quarter. Jelmyto contributed $22.0 million in revenue, with full-year guidance remaining between $97 million and $101 million. H.C. Wainwright also reiterated a Buy rating, maintaining a $75 price target, following UroGen Pharma’s submission of a New Drug Application for UGN-103 to the FDA.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.